Synthetic Biology Startup Funding 2025-2026
In our synthetic biology market deck, you will find everything you need to understand the market
SUMMARY
This report analyzes publicly disclosed equity rounds raised by pure-play synthetic biology companies between July 2025 and June 2026, using a 12-month window and a minimum disclosed equity size of $300K. We define the synthetic biology market as tools, platforms, and products that rely on engineering biological systems using designed DNA, genetic circuits, engineered organisms, or modern biological design methods.
The final dataset includes 15 disclosed equity deals across 15 unique companies. Together, those companies raised $774.84M during the period.
The synthetic biology market is highly concentrated by capital. NewLimit alone represents 56.14% of all disclosed funding, while the top 3 deals account for 76.92%.
The median round size is $13.25M, while the average round size is $51.66M. That gap shows that the market is strongly right-skewed and should not be interpreted through averages alone.
Deal flow in the synthetic biology market is modest but consistent. The dataset averages 1.25 deals per month, with a median of 1.0 deal per month.
Synthetic Biology Therapeutics leads by dollars, with $490.00M raised and 63.24% of total disclosed capital. But it represents only 2 of 15 deals, so its capital leadership is driven by round size, not deal breadth.
Synbio Design Software leads by deal count, with 4 deals and $147.27M raised. This suggests that investors are funding many computational biology and AI-biology infrastructure bets, even when the largest checks still go elsewhere.
Stage distribution is uneven. Series A is the most common stage with 6 deals, but Series C captures 65.69% of all disclosed capital because of large late-stage rounds.
Geographically, North America dominates dollars with $640.00M, or 82.60% of total disclosed capital. Europe matches North America on deal count with 5 deals, but raises far less total capital.
No repeat investor with more than one qualifying disclosed deal was identified. The synthetic biology market in this dataset is concentrated by company size, not by a repeated investor syndicate.
This market map, featured in our synthetic biology market deck, highlights top companies and startups in the synthetic biology market
What are all the funding deals in the synthetic biology market from July 2025 to June 2026?
The table below lists every disclosed equity round raised by pure-play synthetic biology companies between July 2025 and June 2026. We count as “pure-play” synthetic biology companies those where modern engineered biology, biological design, cell programming, engineered microbes, synthetic biology software, or biofoundry infrastructure is central to the company’s activity.
Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors, and the announcement source. For a wider view of how synthetic biology fits into the broader bioeconomy and platform biology opportunity, we cover it in our Synthetic Biology market report.
| Company | What they do | Category | Date | Stage | Deal size | Region | Main investors | Source |
|---|---|---|---|---|---|---|---|---|
| AmphiStar | Develops microbial biosurfactants from bio-based side streams for personal care, home care, and other applications | Synbio Materials Platforms | Jul 2025 | Unknown | $11.7M | Europe | European Innovation Council | European Biotechnology Magazine |
| Provectus Algae | Programs algae using Precision Photosynthesis and AI-enabled biomanufacturing to create bioproducts, including methane-reducing feed supplements | Synbio Food Platforms | Jul 2025 | Series A | $10.1M | Asia-Pacific | At One Ventures | Yahoo Finance |
| NetZeroNitrogen | Develops bacterial seed treatments that let crops access atmospheric nitrogen and reduce use of synthetic nitrogen fertiliser | Engineered Microbes | Jul 2025 | Seed | $6.6M | Europe | Not disclosed in dataset | EU-Startups |
| Scindo | Develops AI-enabled enzyme discovery and design for bio-based ingredients and sustainable chemistry | Synbio Design Software | Sep 2025 | Seed | $5.27M | Europe | Not disclosed in dataset | EU-Startups |
| Profluent | Builds frontier AI models for programmable biology, including design of genome editors, antibodies, and enzymes | Synbio Design Software | Nov 2025 | Series A | $106M | North America | Not disclosed in dataset | Business Wire |
| Cellarim Labs | Develops cell-free biomanufacturing for high-purity beauty and personal-care ingredients | Synbio Materials Platforms | Dec 2025 | Seed | $0.72M | Asia-Pacific | 3i Partners | StartupTalky |
| bit.bio | Programs human cells using opti-ox technology to supply defined cells for research, drug discovery, and cell-identity applications | Biofoundry Platforms | Jan 2026 | Series C | $50M | Europe | Not disclosed in dataset | bit.bio |
| Think Bioscience | Uses synthetic biology, enzymology, protein biophysics, computational chemistry, and medicinal chemistry to unlock difficult drug targets | Synthetic Biology Therapeutics | Jan 2026 | Series A | $55M | North America | Not disclosed in dataset | PR Newswire |
| Antheia | Uses advanced biosynthesis to manufacture pharmaceutical ingredients through engineered biology | Engineered Microbes | Jan 2026 | Series C | $24M | North America | Not disclosed in dataset | Antheia |
| baCta | Builds AI-powered strain engineering and precision-fermentation systems that use microorganisms as programmable molecular factories for industrial ingredients | Engineered Microbes | Mar 2026 | Seed | $8.2M | Europe | Not disclosed in dataset | baCta |
| Cauldron Ferm | Provides advanced continuous-fermentation infrastructure for bioindustrial manufacturing | Biofoundry Platforms | Mar 2026 | Series A | $13.25M | Asia-Pacific | Not disclosed in dataset | Business Wire |
| Scala Biodesign | Provides ScalaOS, an AI-driven protein-design platform for biologics, enzymes, antibodies, vaccines, and industrial protein engineering | Synbio Design Software | Mar 2026 | Series A | $16M | Middle East | Not disclosed in dataset | BioSpace |
| Pumpkinseed | Builds a nanophotonic protein-sequencing platform to generate functional proteomic datasets for biopharma, biosecurity, and AI biology | Synbio Design Software | May 2026 | Series A | $20M | North America | Not disclosed in dataset | Pumpkinseed Bio |
| StrainX Bioworks | Builds a precision-fermentation and synthetic-biology platform for high-value nutritional and flavor ingredients | Synbio Food Platforms | May 2026 | Unknown | $13M | Asia-Pacific | Not disclosed in dataset | AgFunderNews |
| NewLimit | Develops AI-driven epigenetic reprogramming medicines using transcription-factor combinations to restore youthful cellular function | Synthetic Biology Therapeutics | Jun 2026 | Series C | $435M | North America | Not disclosed in dataset | The Wall Street Journal |
In our synthetic biology market deck, we identify pain points entrepreneurs should prioritize
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this synthetic biology funding tracker by reviewing every publicly disclosed equity round raised by pure-play synthetic biology companies between July 2025 and June 2026. A company counts as pure-play when more than 80% of its activity is dedicated to engineering biological systems using designed DNA, genetic circuits, engineered organisms, cell programming, synthetic biology software, or modern biological design methods.
We applied four filters to build the dataset. First, we only included equity rounds, so grants, debt, IPOs, acquisitions, public-company financings, and non-separable blended funding are excluded. Second, we only counted rounds of $300K or more. Third, we only kept pure-play synthetic biology companies. And fourth, every entry had to be confirmed by a direct company announcement, a press release, or a tier-1 media report, with the source URL preserved for every row.
We excluded conventional biotech and pharmaceuticals where synthetic biology was not central to the business model, basic GMOs, and traditional fermentation or bio-based products where modern synthetic biology methods were not central to the design or production process. The final dataset contains 15 disclosed deals across 15 unique companies, and every average, median, share, and concentration ratio is computed on that disclosed equity sample. Privately raised rounds that were never publicly announced are necessarily missing, which is a known limitation of any public-only synthetic biology funding tracker.
How active has fundraising been in the synthetic biology market?
As of June 2026, fundraising in the synthetic biology market has been active but not broad. Over 12 months, pure-play synthetic biology companies raised 15 disclosed equity rounds and $774.84M in total capital.
That equals an average of 1.25 deals per month, with a median of 1.0 deal per month. In practical terms, the market produced a steady trickle of disclosed financing rather than a flood of new rounds.
The dollar total looks much larger than the deal count suggests. Average capital raised per month is $64.57M, but the median month is only $16.84M, which shows that a few large months drive the total.
The synthetic biology market is therefore active, but the activity is uneven. The right reading is that investors are still funding the sector, while remaining selective about which companies deserve large checks.
If you’re interested in knowing more about the top startups in this industry, check our market report covering synthetic biology companies.
How concentrated has fundraising been in the synthetic biology market?
As of June 2026, fundraising in the synthetic biology market is extremely concentrated at the top. Over 12 months, the largest deal accounts for 56.14% of all disclosed capital, and the top 3 deals account for 76.92%.
The concentration becomes even clearer when looking at the top 5 and top 10 deals. The top 5 deals represent 86.47% of capital, while the top 10 represent 96.01%.
This means total funding is not a broad-market measure. It is mostly a measure of how investors valued a small set of companies, especially NewLimit, Profluent, Think Bioscience, bit.bio, and Antheia.
The synthetic biology market has many application areas, but the funding signal is not evenly distributed across them. Any headline about market recovery should first ask whether the claim still holds after removing the top deal.
How much of the synthetic biology funding signal is driven by outliers?
As of June 2026, most of the funding signal in the synthetic biology market is driven by outliers. Over 12 months, just 3 rounds above $50M account for the overwhelming majority of disclosed capital.
NewLimit raised $435M, Profluent raised $106M, and Think Bioscience raised $55M. Together, these three deals explain why the market looks large in dollar terms despite having only 15 qualifying rounds.
Excluding rounds above $50M reduces total disclosed capital from $774.84M to $178.84M. That is a 76.92% drop, which means the typical company is still operating in a much more capital-constrained environment.
The average round size is $51.66M, but the median round size is $13.25M. The median is the better guide to ordinary financing conditions in the synthetic biology market.
For more context on the difference between headline capital and typical company funding, see our deeper analysis of the synthetic biology market.
This chart, featured in our synthetic biology market deck, shows how Twist Bioscience is capturing share in synthetic biology
Is the synthetic biology market broad with many targets, or narrow with few fundable companies?
As of June 2026, the synthetic biology market is broad in scientific scope but narrow in disclosed financing targets. Over 12 months, the dataset includes 15 deals across 15 unique companies, so each qualifying company appears only once.
The category mix shows meaningful breadth. The dataset includes therapeutics, design software, biofoundry platforms, engineered microbes, food platforms, and materials platforms.
But breadth of use cases does not equal breadth of capital access. Synthetic Biology Therapeutics has only 2 deals but receives 63.24% of disclosed capital, while food and materials together have 4 deals but only 4.58% of capital.
So the synthetic biology market is not narrow because there are few application areas. It is narrow because large institutional checks are concentrated in a few narratives with clearer venture-scale upside.
Is synthetic biology mostly an early-stage formation market or a late-stage scaling market?
As of June 2026, the synthetic biology market is split between early-stage deal formation and late-stage capital concentration. Over 12 months, Seed, Series A, and Unknown rounds account for 12 of 15 deals, but Series C rounds account for 65.69% of capital.
Series A is the modal stage by deal count, with 6 disclosed deals and 40.00% of total activity. That shows that many companies are still in platform validation, early commercialization, or first serious institutional financing.
Seed rounds account for 4 deals but only $20.79M, or 2.68% of disclosed capital. This means company formation is alive, but early companies are not being broadly capitalized for expensive wet-lab scale-up.
Series C rounds tell the opposite story. Three Series C deals raised $509.00M, with an average size of $169.67M, so later-stage capital is available when companies fit a large platform or therapeutic narrative.
If you want to learn more about what investors are currently underwriting, check out our report on the synthetic biology market.
Which categories attract the most investor attention in synthetic biology?
As of June 2026, Synbio Design Software attracts the most investor attention by deal count in the synthetic biology market. Over 12 months, it produced 4 of 15 disclosed deals, or 26.67% of the dataset.
That category includes Scindo, Profluent, Scala Biodesign, and Pumpkinseed. The common thread is not generic software, but software tied to physical biological outputs such as enzymes, proteins, genome editors, and proteomic data.
Engineered Microbes ranks second by deal count with 3 deals, or 20.00% of activity. NetZeroNitrogen, Antheia, and baCta show how engineered microbes continue to matter in agriculture, pharma ingredients, and industrial ingredients.
The remaining categories each produced 2 deals. That spread confirms that the synthetic biology market is not a single-product market, even though its capital is heavily skewed toward a few categories.
This chart, featured in our synthetic biology market deck, illustrates yearly funding for synthetic biology startups
Which categories attract disproportionately large checks in the synthetic biology market?
As of June 2026, Synthetic Biology Therapeutics attracts disproportionately large checks in the synthetic biology market. Over 12 months, the category produced only 13.33% of deals but captured 63.24% of disclosed capital.
The capital-share-to-deal-share ratio for Synthetic Biology Therapeutics is 4.74. That means the category receives almost five times more capital share than its deal footprint would imply.
NewLimit and Think Bioscience drive this result. Both companies connect synthetic biology to drug discovery, reprogramming, or therapeutic platform upside, which remains the strongest funding narrative in the sector.
Synbio Design Software is the second-largest capital category, with $147.27M and 19.01% of disclosed capital. But its ratio is only 0.71, which means it is more active by deal count than by average check intensity.
Which geographies matter most for fundraising in the synthetic biology market?
As of June 2026, North America matters most by capital in the synthetic biology market. Over 12 months, North American companies raised $640.00M, or 82.60% of all disclosed funding.
North America does not lead because it has far more deals. It produced 5 deals, the same count as Europe, but its average round size is $128.00M versus Europe’s $16.35M.
Europe is competitive on formation, with 5 deals and $81.77M raised. Its median round size is $8.20M, which shows that European synthetic biology companies are visible but less likely to raise late-stage-sized checks.
Asia-Pacific produced 4 deals and $37.07M, while the Middle East produced 1 deal and $16.00M. Latin America and Africa do not appear in the qualifying disclosed dataset.
If you want to identify where the strongest opportunities are currently emerging, explore our market pitch on synthetic biology.
Is the synthetic biology opportunity set broad or concentrated in one hub?
As of June 2026, the synthetic biology opportunity set is globally visible but capital-concentrated in North America. Over 12 months, North America, Europe, Asia-Pacific, and the Middle East all appear in the disclosed dataset.
North America and Europe each produced 5 deals, so the synthetic biology market is not a one-region formation story. The difference is that North America captures $640.00M, while Europe captures $81.77M.
Asia-Pacific adds another 4 deals, mostly around algae, cell-free biomanufacturing, fermentation infrastructure, and ingredient platforms. That makes the region important for manufacturing and ingredient-oriented synthetic biology, even without North American check sizes.
The Middle East appears through Scala Biodesign, a software-led protein design company. Its presence suggests that regional participation can enter through computational biology, even without a large visible biomanufacturing financing base.
This chart, featured in our synthetic biology market deck, compares the main business model options for synthetic biology platforms
Is synthetic biology a market of small experiments or scaled financings?
As of June 2026, the synthetic biology market is mostly a market of mid-sized experiments with a few scaled financings. Over 12 months, 8 of 15 disclosed rounds sit between $5M and $20M.
Only 1 deal is below $5M, and 3 deals sit between $20M and $50M. Another 3 deals are above $50M, which means megarounds are only 20.00% of deal count but dominate dollar totals.
The median round size of $13.25M is the best signal for the typical company. It suggests that most synthetic biology companies are raising enough to build and validate platforms, not enough to industrialize at full scale.
The average round size of $51.66M tells a different story because it is pulled up by NewLimit, Profluent, and Think Bioscience. In the synthetic biology market, averages describe outliers more than ordinary operating conditions.
If you want to stay on top of the latest trends, risks, and opportunities in this market, check out our market report on synthetic biology.
How important are first financings and follow-on rounds in the synthetic biology market?
As of June 2026, follow-on rounds are more important by capital in the synthetic biology market, while first financings still matter for ecosystem breadth. Over 12 months, the dataset includes both new platform formation and larger repeat-backed companies.
First financings appear in Scindo, Cellarim Labs, baCta, Pumpkinseed, and StrainX Bioworks. These deals show that new company creation is still happening across design software, cell-free manufacturing, engineered microbes, proteomics, and ingredients.
But the largest capital events are follow-ons. NewLimit, Profluent, bit.bio, Think Bioscience, Antheia, and Cauldron all show that larger checks tend to go to companies with existing platform maturity or stronger validation.
This matters because the synthetic biology market should not be judged only by new-company count. Follow-on availability is the better signal for whether investors believe the strongest platforms can keep scaling.
Who are the investors that appear the most in synthetic biology fundraising?
As of June 2026, no investor appears in more than one disclosed qualifying deal in the synthetic biology market. Over 12 months, the dataset shows no repeat investor with more than one disclosed participation across the included rounds.
This does not mean specialist synthetic biology investors are absent. It means the public announcements in this dataset do not reveal a repeated investor pattern strong enough to rank.
The synthetic biology market is therefore concentrated by company size, not by a single repeat syndicate. Large rounds are company-specific events rather than evidence of one investor group controlling the category.
One caveat is important. Funding announcements often disclose total round size and selected investor names, but not each investor’s individual check size. So even when investors are named, dollar-by-investor analysis would be unreliable.
This chart, featured in our synthetic biology market deck, illustrates the share of revenue generated by each customer segment in the synthetic biology market
INSIGHTS
The insights below come from reviewing every disclosed equity round in the synthetic biology market between July 2025 and June 2026. They are not row-by-row summaries. They are the reusable patterns that kept showing up across the 15-deal dataset, and they are meant to stay useful when reading any future synthetic biology funding announcement.
The synthetic biology market’s capital picture is not representative of its company-formation picture. Therapeutics produced only 13.33% of deals but 63.24% of capital. Funding totals mostly measure investor appetite for a few drug-platform narratives, not broad synthetic biology deployment.
NewLimit alone changes the market story. One company accounts for 56.14% of all disclosed capital in the dataset. Any claim that synthetic biology funding has recovered should be tested by removing that single round.
The typical synthetic biology company is still capital constrained. Excluding rounds above $50M reduces total disclosed capital from $774.84M to $178.84M. That shows most companies are not operating in a megaround environment.
The gap between the average and median round is the clearest warning label in the dataset. The average round is $51.66M, while the median is $13.25M. Averages make the synthetic biology market look more liquid than it feels for most companies.
Design software has the strongest deal-count signal. Synbio Design Software leads with 4 deals, which suggests investors are actively funding computational biology infrastructure. But the largest checks still go to therapeutic optionality.
Therapeutic optionality remains the strongest financing multiplier. Synthetic Biology Therapeutics has a capital-share-to-deal-share ratio of 4.74. That is the clearest sign that drug-platform upside still dominates synthetic biology financing economics.
Food and materials are validated at the formation level, not the scale-capital level. Together, those categories produce 26.67% of deals but only 4.58% of capital. Investors are still cautious about underwriting industrial and consumer synthetic biology at large scale.
Biofoundry platforms are funded, but not at therapeutic intensity. Biofoundry Platforms raised 8.16% of capital from 13.33% of deals. The category has investor interest, but not the valuation density of therapeutics or frontier AI-biology platforms.
The most credible non-therapeutic rounds are attached to bottlenecks. Cauldron targets fermentation capacity, Antheia targets pharmaceutical ingredient supply, and baCta targets strain and product economics. Investors are backing constraints, not generic bio-based branding.
Pure software is rarely just software in the strongest synthetic biology rounds. Profluent, Scala, Scindo, and Pumpkinseed all connect computation to physical biological outputs. The funded thesis is design software tied to proteins, enzymes, genome editors, or data-rich biological measurement.
The market prefers picks-and-shovels exposure over direct consumer adoption risk. Enabling layers such as design tools, cell programming, fermentation infrastructure, and proteomic data receive more credible funding signals than branded end products. This reflects caution about margins, regulation, and end-market adoption.
Government-linked funding needs careful decomposition. AmphiStar and Provectus both required separating equity from grant components. In synthetic biology, announced “funding” often overstates private equity capital available to shareholders.
Source quality varies by deal size. Large rounds usually have company announcements, press releases, or tier-one coverage. Smaller industrial biology rounds often rely on regional startup press, which makes small-deal completeness more uncertain.
“Uses fermentation” is not enough to qualify as synthetic biology. The strongest qualifying companies explicitly describe engineered strains, cell programming, programmable microbes, designed proteins, synthetic biology platforms, or biological design systems. This rule helps separate modern synthetic biology from traditional fermentation.
North America wins on capital depth, while Europe competes on formation. Both regions produced 5 deals, but North America raised $640.00M versus Europe’s $81.77M. Europe is visible, but not matching North American late-stage check size.
Asia-Pacific’s visible activity is more manufacturing- and ingredient-oriented. The region produced 26.67% of deals but only 4.78% of capital. That points to practical biomanufacturing activity rather than large therapeutic-platform financing.
The absence of Latin America and Africa is a market-infrastructure signal. No qualifying disclosed rounds appeared from either region. Fundable pure-play synthetic biology remains concentrated where wet-lab infrastructure, specialist investors, and industrial customers are deeper.
Repeat investor absence changes how the market should be read. No disclosed investor appears in more than one qualifying deal. The period’s syndicates look opportunistic and company-specific, not like a tightly repeated synthetic biology investor cartel.
The best future synthetic biology filter is evidence quality, not synthetic biology language. Strong companies should be weighted by design-build-test-learn throughput, manufacturability, customer contracts, and separable equity funding. Language alone is not a strong enough signal.
European Biotechnology Magazine (AmphiStar), Yahoo Finance (Provectus Algae), EU-Startups (NetZeroNitrogen), EU-Startups (Scindo), Business Wire (Profluent), StartupTalky (Cellarim Labs), bit.bio (Series C), PR Newswire (Think Bioscience), Antheia (Series C extension), baCta (Seed), Business Wire (Cauldron Ferm), BioSpace (Scala Biodesign), Pumpkinseed Bio (Series A), AgFunderNews (StrainX Bioworks), The Wall Street Journal (NewLimit)
Related blog posts
- All the funding deals in the synthetic biology market
- The startups that have raised the most funding in synthetic biology
